First patient dosed in IRX-616a Phase 1 trial
Filed with ASX · · 2 pages · English
Summary by 6ix AI
The trial is designed to evaluate the pharmacokinetics, safety, and tolerability of the drug in healthy adult volunteers. A Safety Review Committee meeting is scheduled to assess the suitability of dose escalation for the second cohort.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Nexalis Therapeutics Limited on 6ix
Earlier from Nexalis Therapeutics
- First eligible participant screened - phase 1 IRX-616a study
- Preliminary Final Report
- Dec25 Quarterly Activities Report
- Dec25 Appendix 4C Cash Flow Report
- IRX Overview Presentation - SRX-25 and Nexalis
Later from Nexalis Therapeutics
- Significant Milestone - First Patient Screened IRX-211 Ph2
- Mar26 Appendix 4C Cash Flow Report
- Suspension from Quotation
- Binding Letter of Intent to replace existing $53m facility
- Update on Funding Facility and Clinical Program
Follow Nexalis Therapeutics into a list and get an email when it puts out news.
Follow Nexalis Therapeutics